Lymphoma (includes NHL, HL, CNS Lymphoma)

Why Gilead Could Pay More Than $2 Billion In Deal With This Small S.F. Biotech

(San Francisco Business Times) June 19, 2019 - A small San Francisco drug company offering a new protein-degrading approach to fight blood cancers and other diseases cut a potential $2.3 billion deal with giant Gilead Sciences Inc. to discover drugs that Gilead then could license. In the multi-year deal, Foster City-based Gilead will pay $45 million upfront to privately held Nurix Therapeutics Inc. with the promise of another $2.3 billion if certain research, preclinical, clinical, regulatory and commercial milestones are hit.

read article

FDA Grants Fast Track Designation for Torque's First Deep-Primed T Cell Cancer Immunotherapy Program, TRQ-1501

(Yahoo! Finance) June 18, 2019 - Torque announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Torque's first Deep-Primed™ T cell immunotherapy program, TRQ-1501 (Deep IL-15 Primed T cells).

read article

Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma

(Yahoo! Finance) June 15, 2019 - Forty Seven, Inc. today announced updated data from its ongoing Phase 1b/2 clinical trial evaluating 5F9 in combination with rituximab for the treatment of relapsed/refractory non-Hodgkin’s lymphoma (r/r NHL), including diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma.

read article

Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress

(MarketWatch) June 15, 2019 - Interim results show STRO-001 was generally well tolerated and anti-tumor activity was observed in two patients with recurrent diffuse large B-cell lymphoma (DLBCL)- STRO-001 is the first antibody-drug conjugate generated with Sutro's novel cell-free protein synthesis technology and site-specific conjugation to be tested in the clinic.

read article

Regeneron Says Early-Stage Results Positive for REGN1979 in Lymphoma

(Morningstar/Dow Jones Newswires) June 14, 2019 - Regeneron Pharmaceuticals Inc. said results were positive from early-stage data for REGN1979 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The company said there was a 93% overall response and 71% complete response rates in follicular lymphoma grades 1 to 3a treated with REGN1979 5 mg to 320 mg.

read article

Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures

(Regeneron) June 14, 2019 - Regeneron Pharmaceuticals, Inc. today announced positive early-stage data for REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). The emerging data, which includes patients with R/R diffuse large B-cell lymphoma (DLBCL) who had progressed after CAR-T therapy, will be presented tomorrow at the 24thCongress of the European Hematology Association (EHA).

read corporate press release

ArQule Stock Rockets 49% Toward 12-Year High After Biotech Announces Phase 1 Trial Results

(MarketWatch) June 14, 2019 - Shares of biotech ArQule Inc. shot up 49% toward a 12-year high in premarket trade Friday after the company announced preliminary data from a Phase 1 trial of its investigational cancer drug ARQ 531. The early-stage trial, which is still ongoing, looks at several different doses of the drug in 34 patients with advanced chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), Richter's Transformation, Waldenström macroglobulinemia or other B-cell Non-Hodgkin lymphomas.

read article

ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting

(Yahoo! Finance) June 14, 2019 - ARQ 531 demonstrates substantial anti-tumor activity and favorable safety profile. Four of six evaluable CLL patients, all with the BTK-C481S mutation, from cohort 7 (65 mg) experienced a Partial Response.

read article

Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma

(Kura) June 14, 2019 - Kura Oncology, Inc. today announced updated interim data from the ongoing Phase 2 clinical trial of its lead drug candidate, tipifarnib, in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

read corporate press release

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Congress of the European Hematology Association (EHA) and the International Conference on Malignant Lymphoma (ICML)

(Seattle Genetics) June 12, 2019 - Updated analyses from clinical trials evaluating ADCETRIS in combination with Opdivo® (nivolumab), as well as encore analyses from the phase 3 ECHELON-1, ECHELON-2 and ALCANZA clinical trials, will be highlighted in 12 presentations at EHA and ICML.

read corporate press release

New Phase 2 Clinical Trial Results Continue to Demonstrate Potential Clinical Benefit of IMV’s DPX-Survivac in Combination with Merck’s Keytruda in Patients with DLBCL

(Markets Insider) June 12, 2019 - IMV Inc., a clinical stage immuno-oncology corporation, today announced updated data from the ongoing investigator-sponsored SPiReL Phase 2 clinical trial assessing IMV’s lead candidate, DPX-Survivac, in combination with intermittent low dose cyclophosphamide and Merck’s checkpoint inhibitor Keytruda® (pembrolizumab).

read article

ADC Therapeutics Announces Presentations At The 15th International Conference On Malignant Lymphoma

(ADC Therapeutics) June 12, 2019 - Pyrrolobenzodiazepine-based antibody drug conjugates demonstrate potential for the treatment of relapsed or refractory lymphomas as single agents and in combination therapies.

read corporate press release

TG On Go with U.S. Application for Umbralisib in MZL

(Seeking Alpha) June 11, 2019 - Based on FDA feedback, TG Therapeutics expects to file a U.S. marketing application seeking accelerated approval to use umbralisib to treat marginal zone lymphoma (MZL) by year-end.

read article

Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody®-CD38

(Genmab) June 11, 2019 - Genmab signs agreement with Janssen Biotech, Inc. to collaborate exclusively on next-generation CD38 antibody product, HexaBody®-CD38, incorporating Genmab’s proprietary HexaBody technology. New agreement builds on Genmab’s successful DARZALEX® collaboration with Janssen. Next-generation HexaBody-CD38 could potentially add to the DARZALEX multiple myeloma franchise and expand the potential of CD38-targeted therapies in further indications.

read corporate press release

J&J Takes Option on Genmab Follow-Up to Darzalex

(PMLiVE [UK]) June 11, 2019 - Johnson & Johnson’s longstanding alliance with Genmab has already produced one blockbuster drug for lymphoma – Darzalex – and it is now eyeing a follow-up candidate. The US company’s Janssen Biotech unit has signed an option agreement with Genmab for HexaBody-CD38, billed as a “next-generation” antibody that targets the same CD38 protein as Darzalex (daratumumab) which is approved to treat multiple myeloma and made more than $2bn in sales last year.

read article

FDA Approves First Chemoimmunotherapy Regimen For Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma

(Markets Insider) June 10, 2019 - Today, the U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. Polivy is a novel antibody-drug conjugate, and DLBCL is the most common type of non-Hodgkin lymphoma. "Antibody-drug conjugates are an emerging class of targeted immunotherapies for cancer. This type of therapy, unlike traditional chemotherapy, is intended to target specific cells," said Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.

read article

Xynomic Dosed First Patient in Phase 1/2 Lymphoma Trial

(NASDAQ) June 6, 2019 - Xynomic Pharmaceuticals Holdings, Inc., a clinical stage US-China oncology drug development company, announced that Xynomic has dosed the first patient in a Phase 1/2 trial that combines abexinostat with ibrutinib in patients with relapsed/refractory mantle cell lymphoma ("r/r MCL") or relapsed/refractory diffuse large B-cell lymphoma ("r/r DLBCL") at Memorial Sloan Kettering Cancer Center (MSK).

read article

Innate Pharma Enrolls First Patient In IPH4102 TELLOMAK Phase II Study

(MarketWatch) June 6, 2019 - TELLOMAK is a Phase II study to evaluate the efficacy of IPH4102 in different subtypes of T-cell lymphoma.

read article

Walking Speed Predicts Clinical Outcomes In Older Adults With Blood Cancers

(ASH) June 5, 2019 - Slower walking pace linked to a higher likelihood of death and hospital visits; researchers say gait speed should be used along with other vital signs to better tailor care.

read press release

TG Therapeutics Presents Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting

(Yahoo! Finance) June 4, 2019 - TG Therapeutics, Inc. today presented positive interim data from the ongoing single-arm marginal zone lymphoma (MZL) cohort of its Phase 2b UNITY-NHL trial currently evaluating umbralisib as a single agent in patients with relapsed/refractory MZL.

read article
Next Page